Dave Gallup | EMPIRI - Functional Precision Oncology and Live Tumor Tissue Drug Response

In this episode of Executive Insights for Life Sciences Innovators, Don Alexander speaks with Dave Gallup, Co-Founder and CEO of EMPIRI, an oncology platform company advancing functional precision oncology through its E-slice platform.Dave discusses how EMPIRI is using live human tumor tissue to measure drug response while preserving native tumor architecture and the tumor microenvironment. The conversation explores how E-slice may complement genomic and molecular profiling, help bridge the translational gap between preclinical models and clinical outcomes, and support better decision-making in oncology drug development.Dave also shares his path from building biological analysis businesses to co-founding EMPIRI, including lessons from scaling complex technical platforms, earning market trust, and balancing scientific rigor with commercial execution.This episode covers functional precision oncology, live tumor tissue assays, oncology drug development, translational science, and the future role of empirical drug response data in cancer research and care.This episode was streamed live on YouTube on May 29, 2026. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠genecoda.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.